Summit Therapeutics (SMMT) Change in Acquisitions & Divestments (2023 - 2026)

Summit Therapeutics' Change in Acquisitions & Divestments history runs 4 years deep, the most recent figure standing at $177.3 million for Q1 2026.

• Quarterly Change in Acquisitions & Divestments rose 10.44% year-over-year to $177.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $328.1 million (down 38.96% YoY) and the FY2025 annual result came in at $311.3 million, down 36.44% from the prior year.
• Change in Acquisitions & Divestments was $177.3 million for Q1 2026 at Summit Therapeutics, up from $150.8 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $233.0 million in Q4 2024 and bottomed at $38.2 million in Q2 2023.
• A 4-year average of $118.7 million and a median of $111.1 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• Peak annual rise in Change in Acquisitions & Divestments reached 284.66% in 2024, while the deepest fall reached 32.37% in 2024.
• Summit Therapeutics' Change in Acquisitions & Divestments stood at $60.6 million in 2023, then jumped by 284.66% to $233.0 million in 2024, then slumped by 35.27% to $150.8 million in 2025, then rose by 17.56% to $177.3 million in 2026.
• Business Quant data shows SMMT's Change in Acquisitions & Divestments at $177.3 million in Q1 2026, $150.8 million in Q2 2025, and $160.5 million in Q1 2025.